AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca will invest US$50bn in the US to expand manufacturing and research
AstraZeneca shares show signs of life after successful trials of hypertension drug
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
221.9BUSD
タイプ
Common Stock
取引所
PINK
通貨コード
USD
通貨名
US Dollar
国名
USA
国のISOコード
US
ISIN
GB0009895292
CUSIP
-
セクター
Healthcare
業種
Drug Manufacturers - General
会計年度末
December
上場日
-
更新日時
-
PER
28.55
PEGレシオ
0.95
簿価
26.48
1株当たり配当金
3.1
配当利回り
2.22%
希薄化後1株当たり利益
4.97
ウォールストリートの目標株価
-
EPS見通し(現在の年度)
-
EPS見通し(次の年度)
-
EPS見通し(現在の四半期)
0
EPS見通し(次の四半期)
0
直近の四半期
-
売上高TTM
54,982,000,640
粗利益TTM
45,328,998,400
EBITDA
18,276,999,168
利益率
14.14%
総資産利益率TTM
8.16%
自己資本利益率TTM
19.79%
一株当たり売上高TTM
35.467
四半期売上高成長率(前年同期比)
7.20%
希薄化後EPS TTM
4.97
四半期利益成長率(前年同期比)
33.60%
トレーリングPER
28.55
フォワードPER
15
株価/売上高TTM
4.0009
株価/帳簿価格MRQ
5.3602
企業価値/売上高
4
企業価値/EBITDA
15
70.31
5.29%73.16
3.77%798.16
2.89%190.55
1.95%40.23
1.11%118.02
0.98%168.49
0.35%337.00
0.07%114.52
-3.52%317.30
-1.29%